Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rocket Pharmaceuticals Inc RCKT

Healthcare Biotechnology
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic... see more

Recent & Breaking News (NDAQ:RCKT)

Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference

Business Wire July 8, 2022

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Business Wire May 19, 2022

Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Business Wire May 16, 2022

Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference

Business Wire May 11, 2022

Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

Business Wire May 5, 2022

Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference

Business Wire April 27, 2022

Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire March 29, 2022

Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors

Business Wire March 14, 2022

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

Business Wire March 8, 2022

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

Business Wire February 24, 2022

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference

Business Wire February 10, 2022

Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs

Business Wire January 11, 2022

Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2022

Rocket Pharmaceuticals Presents Positive Clinical Data from Company's Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Business Wire December 13, 2021

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer

Business Wire December 8, 2021

Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Business Wire December 7, 2021

Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference

Business Wire November 22, 2021

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

Business Wire November 15, 2021

Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

Business Wire November 11, 2021

Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference

Business Wire November 10, 2021